Form 4: Travere Therapeutics Director Gary Lyons Executes Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Director Gary Lyons exercised stock options and sold shares of Travere Therapeutics under a pre-arranged 10b5-1 trading plan.
Summary
- On October 4, 2024, Gary Lyons, a director of Travere Therapeutics, exercised stock options to acquire 40,000 shares of common stock at a price of $10.48 per share.
- Lyons then sold 21,179 shares at a weighted average price of $14.3479 (ranging from $13.92 to $14.91) and 18,821 shares at a weighted average price of $15.1547 (ranging from $14.92 to $15.44).
- These transactions were executed under a pre-arranged trading plan (Rule 10b5-1(c)) adopted on March 16, 2023.
- Following these transactions, Lyons directly owns 51,000 shares of Travere Therapeutics common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are part of a pre-planned strategy, and there's no indication of unusual activity or concern.
Positives
- The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.
Risks
- While the transactions are under a 10b5-1 plan, large sales by insiders can sometimes be perceived negatively by the market.
Industry Context
Insider transactions are common and closely monitored in the pharmaceutical industry. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without raising concerns about trading on non-public information.
Comparison to Industry Standards
- Comparing Gary Lyons' transactions to those of other directors in similar-sized biotech companies, the scale of the sale is within a typical range for executives exercising stock options.
- Many biotech executives use 10b5-1 plans to manage their stock sales, similar to executives at companies like BioMarin or Sarepta Therapeutics.
Stakeholder Impact
- The transactions could have a minor impact on shareholders, depending on how the market interprets the insider selling, even under a 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| 2014-10-08 | Date of stock option grant to the Reporting Person with an expiration date of October 8, 2024. |
| 2023-03-16 | Date the Rule 10b5-1(c) written plan was adopted. |
| 2024-10-04 | Date of the transactions: option exercise and stock sales. |
| 2024-10-08 | Expiration date of the stock option granted to the Reporting Person on October 8, 2014. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.